miRNA 221 improved left ventricular contractile function in MIRI mice. by Hongyu Li (1332669)

Subjects:

Significantly Enriched Pathways. by Jiyong Zhang (2498740)

Subjects:

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. by Chen Lu (135200)

Subjects:

Effect of BM-MSCs in improving DCS induced lung injury. by Chen Lu (135200)

Subjects:

Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means. by Mohammad Bakhtiari (11838264)

EF-24 treatment significantly reduces cell viability in leukemia cell lines. by Ajeet P. Singh (22298432)

Subjects:

Bluetooth beacons with colour coded lanyards. by J Mark Ansermino (13958512)

Subjects:

Level classification and summary of total scores of KAP towards hypertension among caregivers at baseline assessment and at week six assessment (n = 422). by Chikondi Maluwa (20660522)

Subjects:

Mean KAP scores and standard deviation at different assessment times. by Chikondi Maluwa (20660522)

Subjects:

Participants’ summary of total KAP scores at different assessment times. by Chikondi Maluwa (20660522)

Subjects:

Socio-demographic characteristics of hypertensive patients’ caregivers (n = 422). by Chikondi Maluwa (20660522)

Subjects:

Participants enrollment. by Chikondi Maluwa (20660522)

Subjects:

Comparison of knowledge retention among different socio-demographic factors using independent t-test (n = 422). by Chikondi Maluwa (20660522)

Subjects:

KAP assessment scores (n = 422). by Chikondi Maluwa (20660522)

Subjects:

Pearson correlation test, correlations between KAP and correlations between age and KAP at baseline and six weeks post-health education (n = 422). by Chikondi Maluwa (20660522)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Overview of the WeARTolerance program. by Ana Beato (20489933)

Subjects: